As a non-invasive therapy, PD-1 inhibition might be a potential treatment option for early-stage lung cancer patients and reduce the second-operation rate for patients with multifocal lesions, especially those inoperable patients with unresected high-risk GGOs. Here, PDCD1 is linked to lung cancer.